Development
NeuroOne Medical Technologies Corporation
NMTC
$0.5817
-$0.0073-1.24%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -6.69% | 9.62% | 1.53% | -103.30% | -26.09% |
| Total Depreciation and Amortization | -6.08% | 9.65% | 29.84% | 22.28% | 7.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.75% | 3.82% | 30.67% | -20.15% | -18.67% |
| Change in Net Operating Assets | -431.56% | -206.51% | 147.93% | 84.91% | -206.02% |
| Cash from Operations | -31.23% | 1.28% | 17.21% | -1.70% | -443.12% |
| Capital Expenditure | 35.59% | 58.65% | 20.72% | -1,427.83% | 82.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | -50.00% | 7,418.80% | 100.90% |
| Cash from Investing | 25.95% | -105.82% | -52.82% | 11,981.46% | 100.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -79.19% | 271.68% | 74.99% | -- | -- |
| Repurchase of Common Stock | -58.14% | 29.51% | 87.64% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 95.50% | -1,528.21% | 69.33% | -967.52% | -- |
| Cash from Financing | -76.79% | 232.65% | 135.77% | 4,316.56% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -217.98% | 531.66% | 51.31% | 69.50% | -73.10% |